NeuBase Therapeutics (NBSE) Appoints Eric J. Ende to its Board

Go back to NeuBase Therapeutics (NBSE) Appoints Eric J. Ende to its Board

NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors

January 5, 2022 4:02 PM UTC

PITTSBURGH and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Eric J. Ende, M.D., to the Company's Board of Directors. Dr. Ende has nearly 25 years of... More